Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes by binding to the L-type calcium channels, leading to coronary vasodilation, decreased myocardial contractility, and slowed AV nodal conduction.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Treatment of hypertension,Management of angina pectoris (chronic stable, vasospastic, unstable),Rate control in atrial fibrillation/flutter,Supraventricular tachyarrhythmias
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous continuous infusion: 5-15 mg/hour (0.25-0.33 mg/kg per hour).
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
3-4.5 hours; prolonged in hepatic impairment (up to 10 hours) and in elderly
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Extensively metabolized in the liver via CYP3A4; undergoes deacetylation, N-demethylation, and O-demethylation; metabolites include desacetyl-diltiazem (active).
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal: 2-4% unchanged; hepatic metabolism with biliary excretion; fecal elimination accounts for ~10%
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
70-80% bound to albumin
Low protein binding; 0–11% bound, primarily to albumin.
5-8 L/kg; indicates extensive tissue binding
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Oral: ~40-50% due to first-pass metabolism; IV: 100%
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
No adjustment required for GFR >10 m L/min; for GFR <10 m L/min, use with caution and monitor heart rate.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
Child-Pugh Class A: reduce dose to 5-10 mg/hour; Child-Pugh Class B: reduce to 2.5-5 mg/hour; Child-Pugh Class C: avoid use.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Children: 0.25-0.33 mg/kg/hour continuous IV infusion; maximum 15 mg/hour.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Elderly: initial dose at lower end of range (5-10 mg/hour); titrate slowly due to increased sensitivity and risk of bradycardia.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
There is no FDA black box warning for diltiazem.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
May cause bradycardia and AV block,Concomitant use with beta-blockers increases risk of bradycardia/heart failure,Avoid in patients with left ventricular dysfunction,May worsen heart failure in patients with reduced ejection fraction,Hepatic impairment requires dose adjustment,Monitor renal function in elderly; may cause hypotension,Avoid abrupt withdrawal
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Sick sinus syndrome (except with pacemaker),Second- or third-degree AV block (except with pacemaker),Severe hypotension (systolic <90 mm Hg),Acute myocardial infarction with pulmonary congestion,Hypersensitivity to diltiazem,Concurrent use with ivabradine
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
Avoid consumption of grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing diltiazem serum concentrations and risk of toxicity. No other significant food interactions.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
No adequate studies in pregnant women. In animal studies, diltiazem has been associated with embryofetal toxicity (skeletal abnormalities, increased mortality) at doses >5 times the maximum recommended human dose. Use only if potential benefit justifies risk. First trimester: potential teratogen, avoid unless essential. Second and third trimesters: may cause uterine hypoperfusion and fetal hypoxia due to maternal hypotension; monitor fetal heart rate and uterine activity if used near term.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Diltiazem is excreted into human milk; milk-to-plasma ratio approximately 0.9. Limited data suggest low levels but potential for adverse effects in nursing infants (bradycardia, hypotension). Consider alternatives, especially while nursing a preterm or low-birth-weight infant. If used, monitor infant for signs of bradycardia and hypotension.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance. No established dose adjustment guidelines; use lowest effective dose. Monitor clinical response and titrate cautiously. Consider starting at lower-end doses (e.g., 30 mg PO QID) and increase based on BP and HR. IV use may require more careful titration due to volume changes.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Diltiazem hydrochloride in 0.72% sodium chloride is an intravenous calcium channel blocker used for rate control in atrial fibrillation/flutter and hypertension. Monitor heart rate and blood pressure closely; may cause bradycardia, hypotension, and heart block. Avoid in patients with sick sinus syndrome or second/third-degree AV block without a pacemaker. The 0.72% sodium chloride concentration provides isotonicity; ensure proper IV access to prevent extravasation tissue necrosis. Contraindicated with concurrent beta-blocker use due to additive bradycardic effects.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This medication is given intravenously to control heart rate or lower blood pressure.,You will have your heart rate and blood pressure monitored continuously during infusion.,Report symptoms of dizziness, fainting, slow heart rate, or difficulty breathing.,Avoid grapefruit juice as it may increase drug levels and side effects.,Do not stop taking other heart medications without consulting your doctor.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Mebendazole, an anthelmintic, inhibits CYP3A4-mediated metabolism of diltiazem, a calcium channel blocker used for hypertension and angina. This results in elevated diltiazem plasma concentrations, increasing the risk of bradycardia, hypotension, and atrioventricular block. Patients may experience enhanced negative chronotropic effects, leading to symptomatic bradycardia or heart block."
"Antipyrine, a substrate of cytochrome P450 (CYP) 3A4, when coadministered with Diltiazem, a moderate inhibitor of CYP3A4, results in decreased metabolic clearance of Diltiazem. This leads to increased plasma concentrations of Diltiazem, potentiating its negative chronotropic and hypotensive effects. Clinically, this interaction may manifest as bradycardia, atrioventricular block, and excessive hypotension."
"Diltiazem, a moderate CYP3A4 inhibitor, can significantly increase the systemic exposure of ceritinib, a sensitive CYP3A4 substrate. This interaction leads to elevated ceritinib plasma concentrations, potentiating its dose-dependent toxicities, including hepatotoxicity, QT interval prolongation, and gastrointestinal disturbances. Concomitant use may require ceritinib dose reduction or temporary discontinuation to mitigate adverse effects."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE is a Electrolyte that works by Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes by binding to the L-type calcium channels, leading to coronary vasodilation, decreased myocardial contractility, and slowed AV nodal conduction.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE is: Intravenous continuous infusion: 5-15 mg/hour (0.25-0.33 mg/kg per hour).. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE is classified as Category A/B. No adequate studies in pregnant women. In animal studies, diltiazem has been associated with embryofetal toxicity (skeletal abnormalities, increased mortality) at doses >5 times th. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.